Kobayashi Yoko Co., Ltd. (8742) AI Stock Analysis

• Market Cap: ¥4.04B
• Dividend Yield: 1.46%
• Average Volume (3M): 39.50K
• Price to Earnings (P/E): 19.7
• Beta (1Y): 0.65
• Revenue Growth: 6.45%
• EPS Growth: -37.80%
• Country: JP
• Employees: 138
• Sector: Financial
• Sector Strength: 70
• Industry: Financial - Capital Markets
• EPS (TTM): 5.19
• Shares Outstanding: 12,554,379
• 10 Day Avg. Volume: 19,040
• 30 Day Avg. Volume: 39,503
• PEG Ratio: -0.43
• Price to Book (P/B): 0.37
• Price to Sales (P/S): 0.78
• P/FCF Ratio: 11.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 76 Outperform
• Price Target: ¥363.00 ▲(13.08% Upside)

Kobayashi Yoko Co., Ltd. demonstrates strong financial performance with consistent revenue growth and robust profitability, which is the most significant factor in the overall score. The technical analysis supports a bullish outlook with positive momentum indicators. Valuation metrics suggest the stock is fairly valued, providing a balanced investment opportunity. The absence of earnings call and corporate events data does not impact the overall score.

Kobayashi Yoko Co., Ltd. Business Overview & Revenue Model

Company Description

Kobayashi Yoko Co., Ltd. (8742) is a Japanese company primarily engaged in the manufacture and sale of consumer health products, pharmaceuticals, and personal care items. Founded in 1904, the company operates across various sectors, including over-the-counter medications, dietary supplements, and skincare products, focusing on improving the quality of life for its customers through innovative and effective solutions.

How the Company Makes Money

Kobayashi Yoko Co., Ltd. generates revenue through the sale of its diverse product range, which includes over-the-counter medications, dietary supplements, and personal care items. The company's revenue model is primarily based on direct sales to consumers and partnerships with retail outlets and pharmacies, which allow for widespread distribution of its products. Key revenue streams include the sales of health-related products in both domestic and international markets. Additionally, the company may benefit from collaborations with other firms for co-branding opportunities or joint ventures, further enhancing its market presence and profitability.

Kobayashi Yoko Co., Ltd. Financial Statement Overview

Summary

Kobayashi Yoko Co., Ltd. showcases a strong financial position with consistent revenue growth and robust profitability metrics. The balance sheet highlights financial stability with low leverage, while cash flow improvements indicate effective cash management. Despite some challenges in net income and cash flow fluctuations, the company's financial health remains solid.

Income Statement

The company has demonstrated consistent revenue growth with a notable increase from 2022 to 2025, achieving a steady rise in gross profit margins, reaching 65.27% in 2025. The net profit margin is also strong at 5.05% in 2025, although it has decreased from the previous year. The EBIT and EBITDA margins show healthy profitability, indicating operational efficiency. Despite these strengths, the drop in net income from 2024 to 2025 suggests potential challenges in maintaining net profitability.

Balance Sheet

Kobayashi Yoko Co., Ltd. maintains a solid balance sheet with a strong equity ratio, as stockholders' equity represents 46.77% of total assets in 2025, reflecting financial stability. The debt-to-equity ratio is low at 0.007, showcasing minimal leverage and reduced financial risk. However, the slight increase in total liabilities over the years may indicate a need for careful debt management. Overall, the company exhibits strong financial health and stability.

Cash Flow

The cash flow statement indicates a positive trend in free cash flow, reversing from negative in 2024 to positive in 2025, reflecting improved cash generation. The operating cash flow to net income ratio is robust at 1.85 in 2025, signaling efficient cash conversion. However, fluctuations in free cash flow growth and negative free cash flow in prior years suggest potential volatility in cash management, warranting attention.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.81B	4.68B	4.49B	4.11B	3.60B	3.45B
Gross Profit	3.14B	3.18B	3.07B	2.80B	2.40B	2.27B
EBITDA	925.09M	303.08M	382.33M	232.11M	-109.05M	-109.08M
Net Income	216.47M	239.41M	370.62M	200.25M	-91.36M	-122.33M
Balance Sheet
Total Assets	22.26B	20.88B	18.47B	16.96B	15.07B	14.20B
Cash, Cash Equivalents and Short-Term Investments	3.12B	3.02B	3.04B	3.28B	3.35B	3.66B
Total Debt	0.00	70.00M	100.00M	19.80M	60.20M	160.60M
Total Liabilities	12.41B	11.11B	8.95B	8.09B	6.45B	5.49B
Stockholders Equity	9.86B	9.77B	9.52B	8.87B	8.62B	7.79B
Cash Flow
Free Cash Flow	0.00	320.77M	-78.00M	117.46M	-120.96M	383.44M
Operating Cash Flow	0.00	443.98M	240.50M	270.71M	-12.25M	543.37M
Investing Cash Flow	0.00	-327.93M	-342.48M	-250.01M	-124.71M	-173.59M
Financing Cash Flow	0.00	-92.61M	36.04M	-71.78M	-133.47M	-53.23M

Kobayashi Yoko Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 321.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8742, the sentiment is Positive. The current price of 321 is below the 20-day moving average (MA) of 323.85, above the 50-day MA of 311.44, and above the 200-day MA of 295.62, indicating a bullish trend. The MACD of 7.05 indicates Negative momentum. The RSI at 72.54 is Negative, neither overbought nor oversold. The STOCH value of 71.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8742.

Kobayashi Yoko Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8747	―	¥9.53B	5.58	―	4.88%	-15.64%	-12.35%
8742	―	¥4.04B	19.69	―	1.46%	6.45%	-37.80%
7175	―	¥6.05B	9.05	―	4.40%	-10.55%	-19.65%
Sector *	―	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
8614	―	¥38.39B	14.42	―	5.48%	6.40%	―
8700	―	¥6.49B	20.05	―	3.72%	4.48%	19.69%
8617	―	¥4.59B	―	―	1.06%	-34.90%	-1619.68%